Stellantis reports strong Q3 results, but warns of one-off charges ahead amid supply chain risks and muted European demand.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.
Stellantis reports strong Q3 results, but warns of one-off charges ahead amid supply chain risks and muted European demand.
FDA updates biosimilars guidance to streamline approvals and boost competition, aiming to cut regulatory barriers and speed lower-cost options to market.